This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.


Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.


As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.





F/G. 1
ATTACHMENTS OF LIGANDS THROUGH PRIMER REGION





ATTACHMENT OF LIGANDS BY INCORPORATION OF MODIFIED NUCLEOTIDE PRECURSORS







FIG. 3


Incorporation of Ligands through Modified Ribonucleotides





F/G. 4
Attachment of Ligands through a 3' tail





F/G. 5
Preparation of Gapped Circle





FIG. 6

Attachment of Ligands through hybridization to a 3' tail





F/G. 7
RNA with Ligands on Primer






FIG. 8
RNA with Ligands on Primer (Continued)






FIG. 9



10/51




FIG. 10

RNA with Ligands on Multiple Primers (Continued)






FIG. 11

Single-stranded DNA with attached Ligands






FIG. 12

Single-stranded DNA with attached Ligands (continued)








FIG. 13

Linear Double-stranded DNA with attached Moieties on each strand










F/G. 15
Enhanced Delivery of Vector
DNA to Haematopoeitic Stem Cell



F/G. 16
Covalent Attachment of vector DNA to Dimeric Antibody






FIG. 17

Covalent attachment of Modified DNA to a Monovalent Antibody






FIG. 18

Modified DNA used as a Binder




$$\begin{array}{c} \text{NH}_2 \\ \text{NH}_2 \\ \text{NH}_2 \\ \end{array} \begin{array}{c} \text{OH} \\ \text{OH} \\ \text{OH} \\ \text{OH} \\ \text{CH}_2 - \text{CH} - \text{CH}_2 - \text{S} \\ \end{array} \begin{array}{c} \text{IV} \\ \text{IV} \\ \end{array} \begin{array}{c} \text{H} \\ \text{H} \\ \text{H} \\ \text{O} \\ \end{array} \begin{array}{c} \text{OH} \\ \text{IV} \\ \text{IV} \\ \end{array}$$

FIG. 19

Synthetic Steps for Creation of Antibodies With Nucleic Acid Moieties Attached








 $\textit{F/G.} \ \ 21$ Enhanced Binding of Antibodies to Antigens by Multimerization





F/G. 22
High Affinity Multi-Insulin Soluble Complex






FIG. 23
Multimerization of Insulin molecules by hybridization to discrete Sequences






FIG. 24


Fusion of Intron into T7 RNA Polymerase Coding Sequence



(A)

Normal T7 RNA polymerase coding sequence

25/51




Synthesis of fragments by PCR Amplification of T7 or SV40 templates



PCR #2


VIII

SV40 Intron



(B)


Fusion of PCR fragments together in eucaryotic expression vector



(C)

Introduction of cassette with AS directed from T7 promoter

T7 terminator sequence



Active T7 RNA polymerase is only made in eucaryotic cells after splicing out of SV40 Intron

FIG. 25
Construction of 17 Expression Vector





5/ Oligomers used for synthesis

GAC TAG TTG GTC TCG TCT CTT TTT TGG AGG AGT GTC GTT CTT AGC GAT GTT AAT C GGA ATT CGT CTC GAG CTC TGA TCA CCA TGG ACA CGA TTA ACA TCG C TSP-2

GGA ATT CGT CTC GGA GAA AGG TAA AAT TCT CTG ACA TCG AAC TGG C **ISP 3**

GAC TAG TGG TCT CCC CTT AGA GAG CAT GTC AGC

GGA ATT CGG TCT CGG GTC TAC TCG GTG GCG AGG

TSP--5

TSP-4

1SP-6

GAC TAG TCG TTA CGC GAA CGC AAA GTC

INI-1 GGA ATT CGT CTC TAA GGT AAA TAT AAA ATT TTT AAG

INT-2 GAC TAG TCG TCT CTG ACC CTA AAA TAC ACA AAC AAT TAG A

FIG. 26

Synthesis of Pieces for Construction of T7 RNA Polymerase with Intron



3' C TAA TTG TAG CGA TTC TTG CTG TGA GGA GGT TTT TTC TCT GCT CTG GTT GAT CAG 5' 5' GG AAT TCG TCT CGA GCT CTG ATC ACC ACC ATG GAC ACG ATT AAC ATC GC Annealing of TSP1 with TSP2

5 Extension of ISP1/TSP2 by polymerase GG AAT TCG TCT CGA GCT CTG ATC ACC ACC ATG GAC ACG ATT AAC ATC GCT AAG AAC GAC ACT CCT CCA AAA AAG AGA CGA GAC CAA CTA GTC CC TTA AGC AGA GCT CGA GAC GTA TGG TGC TAC CTG TGC TAA TTG TAG CGA TTC TTG CTG TGA GGA GGT TTT TTC TCT GCT CTG GTT GAT CAG

Digestion of TSP1/TSP2 product with Bsa I

CC TTA AGC AGA GCT CGA GAC GTA TGG TGG TAC CTG TGC TAA TTG TAG CGA TTC TTG CTG TGA GGA GGT TTT TTC TCT GG AAT TCG TCT CGA GCT CTG ATC ACC ACC ATG GAC ACG ATT AAC ATC GCT AAG AAC GAC ACT CCT CCA AAA AA .

÷

Digestion of PCR #1 clone (pL-1) with BsmB I

5' GGA ATT CGT CTC G

CCT TAA GCA GAG CCTCT

GAGA AAG GTA AAA TTC TCT GAC ATC GAA CTG GC--

TTC CAT TTT AAG AGA CTG TAG CTT GAC CG----

Ligation of Bsa I digested TS1/TS2 product to BsmB I digested PCR#1 clone 5' GG AAT TCG TCT CGA GAC AGA AAG AGG GTA AAA TTC CC TTA AGC AGA GCT CGA GAC GTA TGG TGG TAC CTG TGC TAA TTG TAG CGA TTC TTG CTG TGA GGA GGT TTT TTC TCT TTC CAT TTT AAG

TCT GAC ATC GAA CTG GC-----

AGA CTG TAG CTT GAC CG------

FIG. 27

Formation of Nuclear Localisation Signal by Fusion of TSP1/TSP2 Product to Clone with PCR #1 product



Wild Type T7 nucleic and amino acid sequence

ATG GAC ACG ATT AAC ATC GCT AAG AAC GAC TTC TCT GAC ATC GAA CTG GC --TAC CTG TGC TAA TTG TAG CGA TTC TTG CTG AAG AGA CTG TAG CTT GAC CG--9 10 11 12

Modified T7 nucleic and amino acid sequence with Nuclear Localisation Signal (NLS) insertion

ATG GAC ACG ATT AAC ATC GCT AAG AAC GAC ACT CCT CCA AAA AAG AGA AAG GTA AAA TTC TCT GAC ATC GAA CTG GC-TAC CTG TGC TAA TTG TAG CGA TTC TTG CTG TGA GGA GGT TTT TTC TCT TTC CAT TTT AAG AGA CTG TAG CTT GAC CG-1 2 3 4 5 6 7 8 9 10

FIG. 28

Comparison of the 5' ends of the Nucleotide Sequences of Wild Type and Modified T7 RNA Polymerase






FIG. 29

Fusion of PCR Pieces to Construct T7 RNA Polymerase with an Intron



Oligomers

GAT CAT TAG ACC AGA TCT GAG CCT GGG AGC TCT CTG GCT AAC TAG GGA ACC CAC TGC TTA AGC CTC AAG

GAT CCT TGA GGC TTA AGC AGT GGG TTC CCT AGT TAG CCA GAG AGC TCC CAG GCT CAG ATC TGG TCT AAT

HTB-1 GAT CAC CTT AGG CTC TCC TAT GGC AGG AAG AAG CGG AGA CAG CGA AGA CCT CCT CAA G

HTB-2 GAT CCT TGA GGA GGT CTT CGT CGC TGT CTC CGC TTC TTC CTG CCA TAG GAG AGC CTA AGG T

HTC-1 GAT CAT AGT GAA TAG AGT TAG GCA GGG ATA CTC ACC ATT ATC GGT TCA GAC CCA CCT CCC AG

HTC-2 GAT CCT GGG AGG TGG GTC TGA AAC GAT AAT GGT GAG TAT CCC TGC CTA ACT CTA TTC ACT AT

TER-1 AAT CTA GAG CTA ACA AAG CCC GAA AGG AAG

TER-2 TTC TGC AGA TAT AGT TCC TCC TTT CAG C

Cloning of AS and Terminator sequences into vector with T7 Promoter




FIG. 30

Insertion of Anti-Sense Sequences into **T7** Directed Transcription Units






FIG. 31

Construct with t7 RNA polymerase and Anti-Sense directed from a T7 Promoter




A) Oligomers for introduction of T7 signals and polylinker

TCG AGC CAT GGC TTA AGG ATC CGT ACG TCC GGA GCT AGC GGG CCC ATC GAT ACT PL-1

AGT TAA ATG CAG ATC T

CTA GAG ATC TGC ATT TAA CTA GTA TCG ATG GGC CCG CTA GCT CCG GAC GTA CGG
PL-2
ATC CTT AAG CCA TGG C




Xho I Nco I Afl II Bam H1 Bsi w1 Bsp E1 Nhe I Apa I Cla I Spe I Ase I Pst I (Bam/Bgl)

FIG. 32

Introduction of Poly-Linker for Creation of Protein Expression Vector








FIG. 33

Final steps for construction of Expression Vector





FIG. 34

Construct that produces single-straned Anti-Sense DNA





3; X' Y' Z' 5; 3; A' B' 5; 3; C' 5; 3; A' B' 5; 3; C' 5; 3; A' B' A' 3;

(Structure 35h)
3; X' Y' Z' A' B' C'
3; X' Y' Z' A' B' C'
3; X' Y' Z' A' B' C'
5; X Y Z A B C

(Structure 35k)
3; X' Y' Z' A' B' C'
5; X Y Z A B C

(Structure 35k)
5; X Y Z A B C

(Structure 35k)
6; X' Y' Z' A' B' C'
7; X Y Z A B C

(Structure 35k)
7; X Y Z A B C

(Structure 35k)
7; X Y Z A B C

(Structure 35k)
7; X Y Z A B C

(Structure 35k)
7; X Y Z A B C

(Structure 35k)
7; X Y Z A B C

(Structure 35k)
7; X Y Z A B C

(Structure 35k)
7; X Y Z A B C

(Structure 35k)
7; X Y Z A B C

(Structure 35k)
7; X Y Z A B C


(Structure 35k)
7; X Y Z A B C

(Structure 35k)
7; X Y Z A B C

(Structure 35k)
7; X Y Z A B C

FIG. 35
Continuation of Process from Figure 34





(Structure 36a)

5' X Y Z A B C D

A' B' C' D'

In a series of events similar to that shown for Example G-1, the net products of Rnase H and RT activities on the transcript above create Double stranded DNA products similar to these below

In this example, A B C is a promoter sequence, directing transcription off of these double—stranded DNA products to create RNA transcripts with varying amounts of double—stranded character. Furthermore, the single—stranded loop segment (D to D') of the transcript codes for anti—sense sequences

+ (Structure 36c)

5' Z A B C D

3' A' B' C' D'

+ (Structure 36d)

Z A B C D D'

(Structure 36b)

FIG. 36

Construct that produces RNA that is Reverse Transcribed to create Secondary DNA Constructs capable of directing transcription







FIG. 37

Construct which Propagates a Double Hairpin Production Center





In this Example, the sequence F' E' D' is a promoter, the sequence GHJK is an Anti-Sense sequence and X Y Z is a poly A signal

FIG. 38

Continuation of process from Figure 37






FIG. 39

Construct which propagates a Production Center capable of Inducible Suicide






FIG. 40

Use of tRNA primers to create a DNA construct for secondary production of transcripts




FIG. 41


Excision of sequences from U1 Transcript Region and Replacement with Novel Sequences



(A) Anti-sense oligomers

HVA-1 GAT CCG GAT TGA GGC TTA AGC AGT GGG TTC CCT AGT TAG CCA GAG AGC TCC CAG GCT CAG ATC TGG TCT AAT HVA-2 CCG GAT TAG ACC AGA TCT GAG CCT GGG AGC TCT CTG GCT AAC TAG GGA ACC CAC TGC TTA AGC CTC AAT CCG HVB-1 GAT CCG GAC CTT AGG GAG GTC TCC GCT GTC TCC GCT TCT TCC TGC CAT AGG AGA GCC TAA GGT HVB-2 CCG GAC CTT AGG CTC TCC TAT GGC AGG AAG AAG CGG AGA CAG CGA AGA CCT CCT CAA GGT CCG HVC-1 GAT CCG GAT GGG AGG TGG GTC TGA AAC GAT AAT GGT GAG TAT CCC TGC CTA ACT CTA TTC ACT AT HVC-2 CCG GAT AGT GAA TAG AGT TAG GCA GGG ATA CTC ACC ATT ATC GTT TCA GAC CCA CCT CCC ATC CG HVD-1 GAT CAG CAT GCC TGC AGG TCG ACT CTA AGG GCG AGC TCG GGG TCT AGA GTC GAC CTG CAG GCA TGC T HVD-2 CCG GAT AAT ACG ACT CAC TAT AGG GCG AGC TCG GTA CCC GGG TCT AGA GTC GAC CTG CAG GCA TGC T

(B)Replacment of U1 sequences with HIV Anti-sense sequences



F/G. 42
Insertion of Anti-Sense Sequences into U1 Operons







FIG. 43

Predicted secondary structures for U1 Transcripts with Anti-sense Substitutions





F/G. 44
Construction of U1 Multiple Operon Clone







FIG. 45
Construction of T7 Triple Operon



pNDU1(A,B,C)

Triple U1 Operon Construct with HIV Anti-Sense



TRI 101

Triple T7 Operon Construct with HIV Anti-Sense




FIG. 46

Structures of Triple Operon Constructs from Figures 44 and 45







FIG. 47

Construction of Multiple T7 Operons in Vector coding for T7 RNA Polymerse





300 –

200 -

250 -

150 -

100

20

T							
Global Statistics	, ,	4	17	23	21	69	88
	. apo	78	82	70	2	3	2
	7509 7509 Megn Y	- - - - -					
	Total = 7509 Total = 7509 Mean X Mean Y N	63.65	97.34	70.28	2.34	4.76	3.43
		76.1	15.0	100.0	56.1	45.4	100.0
	74 Counts	5714	.1129	7509	4211	3407	7509
	_0CT05.023 JL_0CT05.02 Bounds	1 78	85 1002	1 1024	2 2	2 1001	2 1001
	1. Green FI 3 JL_OCT05.023 2. Green Log FL JL_OCT05.024 Jist Region Rounds Count	LIN NEG	LIN POS	OVERALL	LOG NEG	LOG POS	OVERALL
	1. Gr Hist	<u> </u>			2		

F/G. 48Flow cytometry data measuring binding of anti -CD4+ antibody to HIV resistant U037 cells

15750 U.S. PTO




FIG. 49

PCR amplification of gag region indicating absence of HIV in viral resistant cell line (2.10.16) after challenge






FIG. 50

Clone with target—lacZ fusion will have reduced expression of lacZ after transfection by HIV Anti—sense construct



(A)

51/51

Enzyme activity as expressed by A₄₂₀ readings in extracts prepared from

	2.5 x 10 ⁴ cells	5 x 10 ⁴ cells	1.0 x 10 ⁵ cells
U 937 (untransfected)	0.018	0.023	0.034
U 937 (HIV A clone)	0.154	0.277	0.566
U937 (HIV A/Anti-A)	0.010	0.017	0.027
U 937 (HIV A/Anti-ABC)	0.013	0.021	0.035
U 937 (HIV A/Null DNA)	0.120	0.212	0.337

(B) Expression of Beta-galactosidase activity by In situ assay:

U 937 (untransfected)	no blue spots in cells
U 937 (HIV A clone)	blue spots in cells
U 937 (HIV A/Anti A)	no blue spots in cells
U 937 (HIV A/Anti ABC)	no blue spots in cells
U 937 (HIV A/Null DNA)	blue spots in cells

FIG. 51

Expression of Beta-galactosidase activity in extracts